Navigation Links
Access Pharmaceuticals to Present at the Noble Financial Equity Conference
Date:8/13/2008

ased on the natural vitamin B12 uptake mechanism; Angiolix(R), a humanized monoclonal antibody which acts as an anti-angiogenesis factor and is targeted to breast cancer; and Prodrax(R), a non-toxic prodrug which is activated in the hypoxic zones of solid tumors to kill cancer cells. Access is also developing Phenylbutyrate ("PB"), an HDAC inhibitor and differentiating agent currently a Phase 2 clinical candidate. For additional information on Access Pharmaceuticals, please visit our website at http://www.accesspharma.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: our ability to close the financing transaction, early results from our clinical trial, Access' plans to continue and initiate clinical trials, the value of its products in the market, its ability to achieve clinical and commercial success and its ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited Access' need to obtain additional financing in order to continue the clinical trial and operations and to the risks detailed in Access' Annual Reports on Form 10-K and other reports filed by Access with the Securities and Exchange Commission.


'/>"/>
SOURCE Access Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. NxStage Announces Access to Demographic and Outcomes Information for the Growing U.S. Daily Home Hemodialysis Patient Population
2. Roche starts acquisition process of ARIUS to gain access to new screening platform for antibody therapeutics
3. AMT Starts Collaboration With St. Jude Childrens Research Hospital on Gene Therapy for Hemophilia B. Company Accesses Exclusive Commercial Rights to Final Therapy
4. Access Pharmaceuticals Signs Merger Agreement to Acquire MacroChem Corp.
5. Huifeng Bio-Pharmaceutical (HFGB) Information to Be Available Through Standard & Poors Market Access Program
6. Access Pharmaceuticals Presents New Data at International Symposium Showing Companys Angiolix(R) Monoclonal Antibody has Potential to Treat Cancer by Attacking Cancer Stem Cells
7. CTI Enters Into Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data for Potential U.S. Supplemental Marketing Application
8. A Perfect Storm Threatens Patient Access to Specialty Medical Care
9. AMT Makes Important Advance in the Development of its Gene Therapy for Hemophilia B -Company Accesses Technology to Prevent Immune Response
10. Access Licenses ProLindac(TM) to Jiangsu Aosaikang Pharmaceutical Co., LTD., a Leading Oncology Pharmaceutical Company for Manufacturing, Development and Commercialization in the Greater China Region
11. HistoRx Announces Expanded Access of AQUA(R) Technology to 900+ Researchers at Dana-Farber/Harvard Cancer Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Automotive, a group of car dealerships headquartered in ... Center and offering free oil change coupons for participation in ... 18 at the Bill Jacobs Cadillac and Chevrolet location from ... )  The Bill Jacobs Auto annual blood ...
(Date:1/15/2014)... 15, 2014 Cynvenio, a cancer diagnostics ... the genomic analysis of tumor cells in the bloodstream, ... web-based cancer decision support application powered by CollabRx, Inc. ... ClearID™ genomic test, Therapy Finder will provide breast cancer ...
(Date:1/15/2014)... A study has been launched to test whether ... could help to tackle the problem of obesity.  This unique ... surgery based in Stowmarket) and academics at University Campus Suffolk ... technology, which is inspired by equipment used to collect data ...
(Date:1/15/2014)... DTS Language Services, Inc . is ... for Life Science organizations who need document translations. Clients ... of their documents in advance with a selection of nearly ... translations, often a critical factor in clinical and scientific fields, ...
Breaking Biology Technology:Join the Bill Jacobs Auto blood drive and receive a free oil change 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4DTS Improves Efficiency for Life Science Document Translations 2
... (Nasdaq: FOLD ) today announced it plans to initiate ... drug in development for the treatment of Pompe Disease. ... pharmacokinetics of AT2220 in muscle tissue in healthy adult subjects. ... to Amicus, proposal for the Phase 1 study and subsequently ...
... PARIS, September 30 , ... to Achieve Similar, Well,Tolerated Glycemic Control Versus Lantus(R) , ... ) announced today results of a,head-to-head study providing further evidence ... [rDNA] injection) compared,to twice-daily insulin detemir. The study was presented ...
... John McPherson, Platform Leader, Cancer Genomics and High-Throughput Screening, ... Institute for Cancer Research (OICR) led a team of ... NEBNext(TM) DNA Sample Prep Reagents for use with OICR,s ... evaluation, "We are constantly striving for the best quality ...
Cached Biology Technology:Amicus Therapeutics Announces Plan to Initiate Phase 1 Study of AT2220 for Pompe Disease 2Amicus Therapeutics Announces Plan to Initiate Phase 1 Study of AT2220 for Pompe Disease 3Amicus Therapeutics Announces Plan to Initiate Phase 1 Study of AT2220 for Pompe Disease 4Superior Efficacy-dose Ratio for Lantus(R) Over detemir 2Superior Efficacy-dose Ratio for Lantus(R) Over detemir 3Superior Efficacy-dose Ratio for Lantus(R) Over detemir 4Superior Efficacy-dose Ratio for Lantus(R) Over detemir 5Ontario Institute for Cancer Research Validates NEBNext(TM) DNA Sample Preparation Reagents from New England Biolabs for use in Next Generation Sequencing 2
(Date:7/9/2014)... about the prevalence of antibiotic-resistant illness, Case Western ... to disabling disease: blocking bacteria,s access to iron ... bacterial siderophore, a small molecule, captures iron from ... as well as how the body launches ... findings appear in a recent edition of ...
(Date:7/9/2014)... may be able to cope with the rising salinity of ... Arctic today is best known for its tundra and polar ... to 38 million years ago during what is known as ... huge temperate forest with brackish water, home to a variety ... and giant tortoises. Much of what is known about the ...
(Date:7/9/2014)... but often can be defeated with antibiotics and then ... Now, scientists have built a new weapon against such pathogens ... journal ACS Applied Materials & Interfaces , their study ... them than medicine alone. , David Leong, Jianping Xie and ... undetectable in the human body or in places that antibiotics ...
Breaking Biology News(10 mins):Bacteria hijack plentiful iron supply source to flourish 2Shark teeth analysis provides detailed new look at Arctic climate change 2Shark teeth analysis provides detailed new look at Arctic climate change 3
... compound found in green tea shows great promise for ... tumors and a deadly congenital disease. The discovery ... Dr. Thomas Smith at The Donald Danforth Plant Science ... Philadelphia. Their findings are published in the recent article, ...
... A research team led by St. Jude Children,s ... for treatment of the childhood eye tumor retinoblastoma. Their ... cancer,s cellular origins are as scrambled as the developmental ... cancers that resemble a particular type of cell, researchers ...
... New research suggests that blood stem cells can be involved ... caused by the abnormal proliferation of mature cells. The study, ... the journal Cancer Cell , may guide future strategies ... CLL is a cancer of a type of mature ...
Cached Biology News:Researchers demonstrate green tea is effective in treating genetic disorder and types of tumors 2Childhood eye tumor made up of hybrid cells with jumbled development 2Childhood eye tumor made up of hybrid cells with jumbled development 3Stem cells central to pathogenesis of mature lymphoid tumors 2
Recombinant Mouse Matrilin-4, CF Protein Family: Extracellular Matrix Molecules, Chondrogenesis Markers...
Request Info...
... labware. Waterproof, moisture-proof film prevents sample ... be folded repeatedly and twisted around ... at 21C (70F), wrapping film increases ... removed, film only partially returns to ...
...
Biology Products: